CEO and Founder: David Horn, M.D., F.A.C.P., F.I.D.S.A.
Dr. Horn brings over 30 years of research expertise in infectious diseases and is board-certified in internal medicine and infectious diseases. Prior to founding Mid-Atlantic Biotherapeutics, Dr. Horn held senior positions in Medical Services and Clinical Development at Merck & Co., Inc., and Professional Services and Medical Affairs at Bristol-Myers Squibb. Dr. Horn has also provided speciality consultancy services to many of the leading pharmaceutical companies. Dr. Horn has designed and performed Phase I-IV clinical trials, and serves on various technology assessment committees. Dr. Horn is board-certified in Internal Medicine and Infectious Diseases, and a fellow of both the American College of Physicians, and the Infectious Disease Society of America. He has authored or co-authored publications concerning HIV infection and AIDS, fungal diseases, bacterial infections, tuberculosis, medical informatics and sepsis.
President and Co-Founder: David Jobes, Ph.D.
Dr. Jobes brings over 20 years of research and business development expertise in virology and HIV. Dr. Jobes received his Ph.D. in cell and molecular biology from Tulane University. After completing his postdoctoral training at the NIH, Dr. Jobes worked at Applied Biosystems, where he was integrally involved in bringing a novel HIV drug resistance kit to market, ViroSeq®. He then moved to VaxGen where he ran a research group that characterized the HIV strains isolated from VaxGen’s two international Phase 3 HIV vaccine trials. This work has resulted in numerous publications studying the effects of the vaccines in MSMs and IV drug users. Prior to founding Mid-Atlantic Biotherapeutics, David was a co-founder of Presidio Pharmaceuticals, a small molecule HIV and HCV therapeutic company, whose lead compound is now in Phase 1 clinical trials.
Senior VP of Operations and Co-Founder: Jean-Pierre Gagnon, Ed.D.
Dr. Gagnon has over 35 years of executive experience in U.S. and International Sales & Marketing, Commercial (P&L) Operations (including President – Merck Mexico). During his career at Merck, Dr. Gagnon was the architect for the launches of several multi-billion dollar brands in the US and led large commercial organizations in Canada, US and Latin America. Dr. Gagnon led the launches and the commercialization of the most successful vaccines and anti-infective brands created by Merck over the last 25 years. In 2013, he graduated with a doctoral degree in Global Business Leadership from the University of Pennsylvania (in collaboration with the Wharton Business School and Thunderbird University). Over the years, Dr. Gagnon has developed an extensive global network of thought leaders, business leaders, human and animal health experts, practitioners, and academicians.